康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的有效性及安全性  

Effectiveness and Safety of Conbercept Assisted Vitrectomy for Proliferative Diabetic Retinopathy

作　　者：刘进清 LIU Jinqing(Department of Fundus Surgery,Fuzhou Southeast Eye Hospital(Jinshan New Hospital),Fuzhou,Fujian Province,350028 China)

机构地区：[1]福州东南眼科医院(金山新院)眼底外科,福建福州350028

出　　处：《糖尿病新世界》2022年第22期167-170,共4页Diabetes New World Magazine

摘　　要：目的分析康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的有效性及安全性。方法选取福州东南眼科医院2019年1月—2022年1月收治的180例增生型糖尿病视网膜病变患者作为研究对象,以随机数字法分为两组,每组90例。对照组单纯应用玻璃体切割治疗,观察组同时联合康柏西普辅助治疗。对比两组的手术时间和患者治疗满意度,统计术中、术后不良事件,比较患者的视力和黄斑中心凹视网膜厚度。结果观察组手术时间为(71.42±12.63)min,患者治疗满意度为(93.23±2.55)分,与对照组相比,差异有统计学意义(P<0.05);观察组术中不良事件发生率为3.33%,低于对照组,差异有统计学意义(P<0.05);观察组术后不良事件发生率为4.35%,低于对照组,差异有统计学意义(P<0.05);治疗后,观察组最佳矫正视力(BCVA)和黄斑中心凹视网膜厚度(CMT)值分别为(4.23±0.33)、(253.48±37.63)μm,与对照组相比,差异有统计学意义(P<0.05)。结论康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变有利于减少术中、术后不良事件,缩短手术时间,改善患者视力,降低视网膜黄斑中心凹厚度,减轻水肿,兼具疗效和安全性。Objective To analyze the efficacy and safety of Conbercept assisted vitrectomy in the treatment of proliferative diabetic retinopathy.Methods 180 patients with proliferative diabetes retinopathy admitted to Fuzhou Southeast Ophthalmic Hospital from January 2019 to January 2022 were selected as the study subjects,and they were divided into two groups by random number method,with 90 cases in each group.The control group was treated with vitrectomy alone,while the observation group was treated with the simultaneous combination of Conbercept adjuvant therapy.The operative time and patient satisfaction with treatment were compared between the two groups,intraoperative and postoperative adverse events were counted,and the patients’visual acuity and retinal thickness in the central macular sulcus were compared.Results The operative time in the observation group was(71.42±12.63)min and the patient treatment satisfaction score was(93.23±2.55)points,compared with the control group,and the difference was statistically significant(P<0.05).The intraoperative adverse events of the observation group was 3.33%,which was lower than the control group,and the difference was statistically significant(P<0.05).The postoperative adverse events in the observation group was 4.35%,which was lower than the control group,and the difference was statistically significant(P<0.05).After treatment,the best corrrected visual acuity(BCVA)and central macular thickness(CMT)values in the observation group were(4.23±0.33)and(253.48±37.63)μm,compared to the control group,and the difference was statistically significant(P<0.05).Conclusion Conbercept adjuvant vitrectomy for proliferative diabetic retinopathy is beneficial in reducing intraoperative and postoperative adverse events,shortening the operative time,improving patients’visual acuity,reducing the thickness of the macular central recess of the retina and edema,combining efficacy and safety,and is worth using.

关 键 词：康柏西普 玻璃体切割 增生型糖尿病视网膜病变 有效性 安全性 

分 类 号：R774[医药卫生—眼科]